The balanced performance saw companion animal sales rise by 10%, while the farm animal segment grew by 6.7%. Management attributed the results to a combination of volume and mix effects contributing 5.4% to the total, supplemented by a 2% price increase. The recent acquisition of Thyronorm proved significant, accounting for 1.4 percentage points of the overall growth.

Geographically, North America led the expansion with double-digit gains, successfully offsetting temporary hurdles in toll manufacturing. European and international markets followed with growth rates of 6.5% and 7.5% respectively. CEO Paul Martingell highlighted the resilience of the portfolio against a difficult external backdrop, noting that the integration of Thyronorm has already begun to generate commercial synergies in the endocrinology sector. Based on these figures, Virbac confirmed its full-year guidance, targeting the upper bound of its 5.5% to 7.5% revenue growth range and an adjusted recurring operating income margin near 17%.